The role of diet in inflammatory bowel disease: A comprehensive review of the literature
- PMID: 40769614
- DOI: 10.1016/j.bpg.2025.101995
The role of diet in inflammatory bowel disease: A comprehensive review of the literature
Abstract
Diet is increasingly recognized as a modifiable factor in the pathogenesis and management of inflammatory bowel disease (IBD), particularly in mild to moderate cases. While most evidence comes from pediatric studies, adult data, especially randomized controlled trials (RCTs), remain limited. Current guidelines recommend a Mediterranean diet for patients with IBD, avoiding fruits and vegetables during disease flares. Exclusive enteral nutrition (EEN) has demonstrated therapeutic potential in pediatric Crohn's disease (CD), but data in adults are less conclusive, partly due to issues with adherence. Clinicians must routinely monitor nutritional markers such as hemoglobin, iron status, vitamins, and albumin every 6-12 months, and supplement deficiencies as required. The presence of a dedicated nutrition specialist within IBD units could improve care, as nutrition also impacts psychological well-being. In addition, the role of the microbiome and how dietary interventions can modulate it to alleviate both inflammatory and functional symptoms warrant further exploration.
Keywords: Crohn's disease; Diet; Inflammatory bowel disease; Nutrition; Ulcerative colitis.
Copyright © 2025. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest F D'Amico has served as a speaker for Abbvie, Ferring, Sandoz, Janssen, Galapagos, Takeda, Tillotts, and Omega Pharma; he also served as an advisory board member for Abbvie, Ferring, Galapagos, Janssen, and Nestlè. M Allocca has received consulting fees from Nikkiso Europe, Mundipharma, Janssen, AbbVie, Ferring, and Pfizer. F Furfaro received consulting fees from Amgen, AbbVie and lecture fees from Janssen and Pfizer. S Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millennium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. A Zilli received lecture fees from AbbVie, Galapagos, Janssen, Tillots Pharma and Takeda and served as a consultant for AbbVie and Galapagos. I Faggiani, S Massironi and TL Parigi declare no conflict of interest.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
